News | June 12, 2013

Patients and Technologists Benefit from Image Reconstruction Software

UltraSPECT partnership with PharmaLogic results in quick success with hospitals

June 12, 2013 — UltraSPECT, a provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announced the installation of its proprietary Wide Beam Reconstruction (WBR) software at nearly 10 healthcare facilities. The installations came as a result of the recent agreement between UltraSPECT and radiopharmaceutical provider PharmaLogic, under which PharmaLogic offers the WBR software as part of its patient-centered approach.

WBR addresses concerns about patient radiation exposure and improved image quality. It enhances the performance of existing NM cameras, enabling a 50 percent reduction in ASNC-recommended radiopharmaceutical injected dose, reducing imaging scan time up to 50 percent while maintaining the full level of image quality. The technology, sold as part of the UltraSPECT Xpress.Cardiac, Xpress3.Cardiac and Xpress.Bone products, can be utilized with most major manufacturers’ NM systems, as well as all clinical software packages. 

"The industry’s growing interest to reduce radiation exposure to patients and to the technologists performing the exams led us to look for a cost-effective, low-dose solution, resulting in our incredibly successful partnership with UltraSPECT,” said Steve Chilinski, president and CEO of PharmaLogic. “We believe these initial installations are just the start of a growing demand for the solution as all of our nuclear medicine customers see that everyone from patients and technologists to physicians, pharmacies and pharmacy staff will benefit.”

UltraSPECT is the only company to offer the proprietary software solution — approved by the U.S. Food and Drug Administration (FDA) — that can be retrofit into existing SPECT (single-photon emission computed tomography) imaging systems. The UltraSPECT Xpress line of products can be readily installed on current gamma camera systems. Utilizing the proprietary WBR iterative reconstruction algorithm, which simultaneously addresses resolution recovery and noise reduction for low-count density, it provides high image resolution for greater lesion localization, raising diagnostic confidence and precision. The products minimize radiation exposure for both patients and technologists, while abbreviated acquisition times reduce the possibility of patient motion artifacts and enhance patient throughput and comfort. For many WBR users, the result is enhanced equipment utilization, revenues, patient satisfaction and referrals.

Huntington Internal Medicine Group (HIMG), Huntington, W.Va., recently selected the UltraSPECT Xpress.Cardiac and Xpress.Bone solutions as part of their partnership with PharmaLogic. "When we learned about UltraSPECT’s WBR technology, we knew immediately that we needed it, and the results have been even better than what we had expected,” said Juanita Dempsey, cardiology and radiology manager at HIMG. “Not only does the ability of the software to enable half of the radioactive dose help protect our patients, but it’s greatly protecting our technologists who are overseeing the procedures again and again."

UltraSPECT is highlighting its WBR software at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), being held in June 9-12 in Vancouver, British Columbia.

For more information: www.ultraspect.com

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
The images (before and after) depict a 50 percent dose reduction in chest X-ray without compromising  image quality.

The images (before) depict a 50 percent dose reduction in chest X-ray without compromising
image quality.

Sponsored Content | Case Study | Radiation Dose Management | July 03, 2018
There are a handful of priorities for radiologists: lowest radiation dosage, highest image quality, optimal workflow,...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Overlay Init